Lv41
700 积分 2024-05-11 加入
Targeting KRAS in cancer
9天前
已完结
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer
9天前
已完结
The Function of RAS Mutation in Cancer and Advances in its Drug Research
9天前
已完结
Abstract LB_C09: QTX3034, a potent and selective multi-KRAS inhibitor, synergizes with EGFR inhibitors and enhances anti-tumor activity
14天前
已关闭
Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC
16天前
已完结
Targeting KRAS in cancer
18天前
已完结
RAS-targeted therapies: is the undruggable drugged?
18天前
已完结
Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers
23天前
已完结
Visualizing differences in ligand‐induced β‐arrestin–GFP interactions and trafficking between three recently characterized G protein‐coupled receptors
2个月前
已完结
Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure
2个月前
已完结
皖公网安备34019202002308
